A new way to prevent HIV delivers dramatic results in trial

For over a decade, taking a pill like Truvada every day has been the standard of care for HIV prevention efforts.

In clinical trials, this type of preventive drug, called pre-exposure prophylaxis (PrEP), can be 99 percent effective in stopping new HIV infections from sex. In the real world, however, that is not always the case.

People don’t always take their pills. In a study in South Africa, women said they felt there was a stigma to the pill — a sexual partner might assume they’re taking it because they already have HIV or because they have other partners.

Now a new trial — called PURPOSE 1 — points the way to a new preventive strategy — a twice yearly injection of a drug called lenacapavir. The trial was sponsored by Gilead Sciences, the California-based maker of the drug.

In this double-blind, randomized study of 5,300 cisgender women in South Africa and Uganda, 2,134 got the injection and the others took one of two types of daily PrEP pills. The trial began on August 2021 and, so far, not a single woman who received the injections has contracted HIV. The participants who received either of the oral PrEP options, Truvada and Descovy, had infection rates of about 2 percent — consistent with the infection rates of oral PrEP in other clinical trials.

These results were significant enough for the Data Monitoring Committee — an independent group of experts appointed to assess the progress of clinical trials — to recommend that Gilead halt its blinded trial and offer lenacapavir to all study participants. On June 20, Gilead announced these results, and now, all participants can choose to receive the injection.

The study’s focus on women in sub-Saharan Africa is based on HIV data. Despite accounting for 10 percent of the world’s population, sub-Saharan Africans comprise two-thirds of people living with HIV — 25.7 million out of 38.4 million. And, every week, about 4,000 teen girls and young women in Africa are newly infected with HIV.

Early reaction is positive

The trial has yet to be peer-reviewed, but these early results have been met with excitement.

“It’s fantastic,” says Dr. Jason Zucker, an assistant professor of medicine and infectious disease expert at Columbia University Vagelos College of Physicians and Surgeons. “It’s hard to take a medication every single day. A medication that is [given] every 6 months has a lot of potential.”

Dr. Philip Grant, clinical associate professor and director of the HIV clinic at Stanford University School of Medicine, agrees that lenacapvir could help fill a gap in prevention options. “It would be a big benefit in populations that have adherence challenges,” he says.

Despite being 99 percent effective in some trials, oral PrEP effectiveness drops significantly in the real-world. One study showed PrEP effectiveness to be as low as 26 percent in certain populations — men under age 30, for example.

“Medications work when you take them,” says Zucker. “A medication that is given every six months has a lot of potential because, essentially, if you can make two visits a year, you are protected for an entire 12 months.”

Advocacy groups have also expressed enthusiasm about lenacapavir’s preliminary results as a PrEP option. “Lenacapavir would be “a real game-changer,” particularly for people facing stigma and discrimination in low- and middle-income countries,” read a statement by People’s Medicines Alliance — a global coalition of more than 100 organizations that span 33 countries and that advocate for making medications more accessible.

The drug isn’t new; the usage is

Lenacapavir is not a new drug. It’s been approved by the FDA in the United States for multi-drug resistant HIV treatment since 2022. But PURPOSE 1 is the first clinical trial to test it for HIV prevention.

The PURPOSE 1 trial is part of a larger initiative to improve HIV prevention across the global south. It is one of several studies that are part of ongoing efforts to end the HIV epidemic by 2030.

An ongoing PURPOSE 2 trial is analyzing lenacapavir’s efficacy among cisgender men, transgender men, transgender women and non-binary individuals who have sex with partners assigned male at birth in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the United States.

Any eventual approval and widespread use would come with challenges. According to an analysis presented at the 24th International AIDS Conference (AIDS 2022), PrEP medications would needto cost less than $54 a year per patient for South Africa, for example, to afford them. Lenacapavir’s cost as HIV treatment in the United States in 2023 was $42,250 per new patient per year. Oral PrEP options, on the other hand, can cost less than $4 a month.

“The biggest gap in prevention isn’t medication, it’s accessing medications,” says Dr. Grant.

Activists across Uganda and South Africa[MIG5] have urged Gilead Sciences to license lenacapavir to the Medicines Patent Pool — a United Nations-backed organization that partners with governments, industry and other organizations to license medications. This would allow for manufacturing of generic versions of the drug at a fraction of the cost.

These activists fear that history will repeat itself: In 2021, cabotegravir. a long-acting injectable PrEP medication manufactured by ViiV Healthcare, was FDA-approved. The medication is more effective than oral options and only requires 2 injections every 2 months.

But despite approval for generic versions of the medication, these versions still have to go through the World Health Organization review process to show they are equally effective to the brand version. Because this process takes time, generic cabotegravir will likely not be available in Africa until 2027.

Since sharing lenacapavir’s early success, Gilead has announced that they intend to “deliver lenacapavir swiftly, sustainably and in sufficient volumes, if approved, to high-incidence, resource-limited countries.” Their access strategy includes developing a voluntary licensing program that would enable generic versions to be produced before the original patent expires. When NPR asked Dr. Jared Baeten, Gilead’s vice president of HIV Clinical Development, about timeframes, he said that estimates will depend on "another trial, a regulatory review and approval."

“Cost is going to play into this dramatically,” says Dr. Zucker, “I think and hope we will do everything we can to try to reduce barriers to access.”

Copyright 2024 NPR

• Suicides in the U.S. military increased in 2023, continuing a long-term trend
• MinnesotaCare applications now open to Minnesotans regardless of immigration status
• How are you feeling a week after the election?
• What happens when a vaccine skeptic leads health policy? Ask Florida